General Information of Drug (ID: DMEYQPN)

Drug Name
P-1736 Drug Info
Synonyms Pyyy; GPR40 modulators (diabetes), Nicholas Piramal; GPR40 modulators (diabetes), Piramal Life Sciences; P-1736-05; GPR40 modulators (diabetes), NPIL Research & Development
Indication
Disease Entry ICD 11 Status REF
Diabetic complication 5A2Y Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMEYQPN

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
TAK-875 DMIM5AP Type-2 diabetes 5A11 Phase 3 [2]
Fasiglifam hemihydrate DMTGYSO Type-2 diabetes 5A11 Phase 3 [3]
PBI-4050 DMPXK27 Idiopathic pulmonary fibrosis CB03.4 Phase 2 [4]
JTT-851 DMED5J6 Type-2 diabetes 5A11 Phase 2 [5]
SHR0534 DMGFTAI Type 2 diabetes 5A11 Phase 1 [6]
LY-2881835 DM5EXJV Type-2 diabetes 5A11 Phase 1 [5]
P11187 DMXZOI0 Type-2 diabetes 5A11 Phase 1 [5]
CPL207-280CA DMFMGZR Type 2 diabetes 5A11 Phase 1 [6]
LY2922470 DMGLTE2 Type 2 diabetes 5A11 Phase 1 [7]
CNX-011-67 DM1H8D6 Type 2 diabetes 5A11 Preclinical [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Free fatty acid receptor 1 (GPR40) TTB8FUC FFAR1_HUMAN Modulator [1]

References

1 Discovery of p1736, a novel antidiabetic compound that improves peripheral insulin sensitivity in mice models. PLoS One. 2013 Oct 23;8(10):e77946.
2 Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab. 2015 Jul;17(7):675-81.
3 A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLoS One. 2013 Oct 10;8(10):e76280.
4 Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2019 Mar 18;53(3):1800663.
5 Treatment of Type 2 Diabetes by Free Fatty Acid Receptor Agonists. Front Endocrinol (Lausanne) 2014; 5: 137.
6 Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Discov. 2020 Jan;19(1):57-75.
7 The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470). J Med Chem. 2016 Dec 22;59(24):10891-10916.
8 CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients. BMC Pharmacol Toxicol. 2014 Mar 25;15:19.